Baheal renames itself as it expands into drug development and manufacturing
November 13, 2026
Source: drugdu
23
Qingdao Baheal Medical announced on November 11 that it had completed the corporate registration for its renaming as Baheal Pharmaceutical Group. Its Chinese stock short name changed on November 12, and its stock code remains 301015.
Baheal acquired Shanghai Baheal Pharmaceutical in 2024, extending its business from commercialization into drug development and manufacturing. The company said its manufacturing operations would support its international expansion.
Source: http://finance.eastmoney.com/a/202611123929870533.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- GSK’s application for marketing approval in China for its recombinant herpes zoster vaccine pre-filled syringe formulation has been accepted. November 13, 2026
- Novo Nordisk has submitted an application for marketing approval in China for its once-weekly subcutaneous injection of CagriSema, for long-term weight management. November 13, 2026
- Colombia’s INVIMA approves Sinotherapeutics’ generic posaconazole delayed-release tablets November 13, 2026
- Sansure Biotech receives China registration for a liver cancer diagnostic kit November 13, 2026
- Everest Medicines receives China approval for 100 mg eravacycline injection November 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
